| Identification | Back Directory | [Name]
2-Propen-1-one, 1-[(2S,4R)-4-[[5-chloro-2-[(1-ethyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-2-methyl-1-pyrrolidinyl]- | [CAS]
2673196-75-1 | [Synonyms]
JAK3/BTK-IN-5
2-Propen-1-one, 1-[(2S,4R)-4-[[5-chloro-2-[(1-ethyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-2-methyl-1-pyrrolidinyl]- | [Molecular Formula]
C19H22ClN7O2 | [MOL File]
2673196-75-1.mol | [Molecular Weight]
415.88 |
| Hazard Information | Back Directory | [Uses]
JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, example 35)[1] | [References]
[1] Baoguo Zhang, et al. Pyrimidinopyrimidine and pentacyclic derivatives and their applications. Patent WO2021147953A1. |
|
|